Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)

11/19/2021 | 06:11am EST

Item 1.01 Entry into a Material Definitive Agreement.

On November 16, 2021, Mirum Pharmaceuticals, Inc. (the "Company") entered into an asset purchase agreement (the "Agreement") with Janssen Biotech, Inc. ("Buyer"), an affiliate of Johnson & Johnson, pursuant to which the Company agreed to sell its Rare Pediatric Disease Priority Review Voucher ("PRV") to Buyer. The Company was awarded the PRV by the U.S. Food and Drug Administration on September 29, 2021 in connection with the approval of LIVMARLI™ (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Pursuant to the Agreement, Buyer agreed to pay the Company $110.0 million, payable in cash, upon the closing of the PRV purchase.

The Agreement contains customary representations, warranties, covenants and indemnification provisions subject to certain limitations. The transaction remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

The foregoing description of the material terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, a copy of which is filed herewith as Exhibit 10.1 and incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K (this "Current Report") contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the completion of the transactions contemplated by the Agreement. Statements using words such as "expect", "anticipate", "believe", "may", "will" and similar terms are also forward-looking statements. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption "Risk Factors" in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligations to make any revisions to the forward-looking statements contained in this Current Report or to update them to reflect events or circumstances occurring after the date of this Current Report, whether as a result of new information, future developments or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.      Description

10.1¥              Asset Purchase Agreement, dated November 16, 2021, by and
                 between the Registrant and Janssen Biotech, Inc.

104              Cover Page Interactive Data File (embedded within the Inline XBRL

¥                Schedules have been omitted pursuant to Item 601(a)(5) of
                 Regulation S-K. The registrant undertakes to furnish supplemental
                 copies of any of the omitted schedules upon request by the SEC.


© Edgar Online, source Glimpses

12:55pSVB Leerink Adjusts Mirum Pharmaceuticals' Price Target to $46 from $42, Keeps Outperfo..
01/19CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Acc..
01/12Raymond James Adjusts Mirum Pharmaceuticals Price Target to $70 From $69, Maintains Str..
01/11Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
01/11MIRUM PHARMACEUTICALS : Provides Business Update and Highlights Key 2022 Corporate Milesto..
01/11MIRUM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Regulation FD..
01/11Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milest..
01/10Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/04Mirum Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference o..
01/03Immix Biopharma Shares More Than Double on FDA Designation
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations